Total Payments
$143,463
2024 Payments
$7,403
Companies
24
Transactions
71
Payment Breakdown by Category
Consulting$66,152 (46.1%)
Research$50,265 (35.0%)
Travel$15,915 (11.1%)
Other$8,725 (6.1%)
Food & Beverage$2,407 (1.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $66,152 | 25 | 46.1% |
| Unspecified | $50,265 | 1 | 35.0% |
| Travel and Lodging | $15,915 | 11 | 11.1% |
| Honoraria | $8,725 | 3 | 6.1% |
| Food and Beverage | $2,407 | 31 | 1.7% |
Payments by Type
General
$93,198
70 transactions
Research
$50,265
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Keryx Biopharmaceuticals, Inc. | $51,605 | 9 | $0 (2017) |
| Pharmacosmos Therapeutics Inc. | $26,541 | 9 | $0 (2024) |
| American Regent | $12,032 | 4 | $0 (2020) |
| AKEBIA THERAPEUTICS INC | $8,132 | 6 | $0 (2021) |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | $7,989 | 8 | $0 (2018) |
| GlaxoSmithKline, LLC. | $6,900 | 2 | $0 (2023) |
| Vifor (International) Ltd. | $5,600 | 2 | $0 (2023) |
| La Jolla Pharmaceutical Company | $4,733 | 5 | $0 (2018) |
| Rockwell Medical, Inc. | $4,300 | 2 | $0 (2020) |
| Incyte Corporation | $3,575 | 3 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,403 | 3 | Pharmacosmos Therapeutics Inc. ($6,743) |
| 2023 | $10,438 | 5 | GlaxoSmithKline, LLC. ($6,500) |
| 2022 | $16,499 | 5 | Pharmacosmos Therapeutics Inc. ($13,299) |
| 2021 | $11,508 | 6 | Pharmacosmos Therapeutics Inc. ($4,225) |
| 2020 | $19,290 | 9 | American Regent ($5,613) |
| 2019 | $10,772 | 9 | American Regent ($6,389) |
| 2018 | $15,209 | 17 | Vifor Fresenius Medical Care Renal Pharma Ltd. ($7,989) |
| 2017 | $52,345 | 17 | Keryx Biopharmaceuticals, Inc. ($51,605) |
All Payment Transactions
71 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/07/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $125.85 | General |
| Category: HEMATOLOGY | ||||||
| 08/07/2024 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Travel and Lodging | In-kind items and services | $6,616.90 | General |
| Category: HEMATOLOGY | ||||||
| 03/13/2024 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $660.00 | General |
| 08/26/2023 | Chugai Pharmaceutical Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $1,170.00 | General |
| 08/26/2023 | Chugai Pharmaceutical Co., Ltd. | — | Food and Beverage | In-kind items and services | $68.42 | General |
| 06/14/2023 | Agios Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 03/13/2023 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $6,500.00 | General |
| 01/16/2023 | Vifor (International) Ltd. | — | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| 12/11/2022 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $27.99 | General |
| Category: HEMATOLOGY | ||||||
| 10/25/2022 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| Category: HEMATOLOGY | ||||||
| 10/10/2022 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Food and Beverage | In-kind items and services | $156.49 | General |
| Category: HEMATOLOGY | ||||||
| 09/05/2022 | Vifor (International) Ltd. | — | Consulting Fee | Cash or cash equivalent | $3,200.00 | General |
| 08/08/2022 | Pharmacosmos Therapeutics Inc. | MONOFERRIC (Drug) | Travel and Lodging | In-kind items and services | $7,114.17 | General |
| Category: HEMATOLOGY | ||||||
| 07/21/2021 | Pharmacosmos Therapeutics Inc. | Monoferric (Drug) | Honoraria | Cash or cash equivalent | $1,950.00 | General |
| Category: Hematology | ||||||
| 06/16/2021 | Pharmacosmos Therapeutics Inc. | Monoferric (Drug) | Honoraria | Cash or cash equivalent | $2,275.00 | General |
| Category: Hematology | ||||||
| 05/18/2021 | Novartis Pharmaceuticals Corporation | JAKAFI (Drug) | Consulting Fee | Cash or cash equivalent | $1,446.00 | General |
| Category: ONCOLOGY | ||||||
| 05/13/2021 | Alnylam Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $615.00 | General |
| 04/22/2021 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,222.00 | General |
| 03/23/2021 | AKEBIA THERAPEUTICS INC | Auryxia (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Nephrology | ||||||
| 12/21/2020 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $1,375.00 | General |
| 12/17/2020 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $1,375.00 | General |
| 11/16/2020 | Otsuka Pharmaceutical Development & Commercialization, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,207.50 | General |
| 11/05/2020 | AKEBIA THERAPEUTICS INC | AURYXIA (Drug) | Consulting Fee | Cash or cash equivalent | $2,320.00 | General |
| Category: NEPHROLOGY | ||||||
| 09/16/2020 | Rockwell Medical, Inc. | TRIFERIC (Drug) | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| Category: END STAGE RENAL DISEASE | ||||||
| 09/08/2020 | Pharmacosmos Therapeutics Inc. | Monoferric (Drug) | Consulting Fee | Cash or cash equivalent | $2,275.00 | General |
| Category: Hematology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 2015-FC-033 | Keryx Biopharmaceuticals, Inc. | $50,265 | 1 |
About Dr. Tomas Ganz, MD
Dr. Tomas Ganz, MD is a Pulmonary Disease healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083639264.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Tomas Ganz, MD has received a total of $143,463 in payments from pharmaceutical and medical device companies, with $7,403 received in 2024. These payments were reported across 71 transactions from 24 companies. The most common payment nature is "Consulting Fee" ($66,152).
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Los Angeles, CA
- Active Since 07/12/2006
- Last Updated 06/23/2010
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1083639264
Products in Payments
- Auryxia (Drug) $53,605
- MONOFERRIC (Drug) $20,041
- INJECTAFER (Drug) $12,161
- Venofer (Drug) $7,989
- Monoferric (Drug) $6,500
- TRIFERIC (Drug) $4,300
- AURYXIA (Drug) $2,591
- JAKAFI (Drug) $1,446
- DEFERIPRONE (Drug) $282.92
- FERRIPROX (Drug) $125.00
- NO PRODUCT DISCUSSED (Drug) $125.00
- Alprolix (Drug) $73.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Los Angeles
Prof. Toby Maher, Md, MD
Pulmonary Disease — Payments: $1.1M
Pulmonary Disease $1.1M
Donald Tashkin, Md, MD
Pulmonary Disease — Payments: $646,650
Pulmonary Disease $646,650
Rajan Saggar, Md, MD
Pulmonary Disease — Payments: $426,392
Pulmonary Disease $426,392
John Belperio, Md, MD
Pulmonary Disease — Payments: $308,808
Pulmonary Disease $308,808
Christopher Cooper, Md, MD
Pulmonary Disease — Payments: $207,817
Pulmonary Disease $207,817
Robert Strieter, Md, MD
Pulmonary Disease — Payments: $172,942
Pulmonary Disease $172,942